Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib rechallenge in EGFR-mutated advanced NSCLC
NL-OMON28936Phase 2Not yet recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Disease control rate. Planned start Feb 2013; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON28936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28936.